Natural Killer receptors distribution in Multiple Sclerosis

  • J E Martinez-Rodriguez
  • M López-Botet
Open Access
Poster presentation


Multiple Sclerosis Multiple Sclerosis Patient Clinical Variable Female Gender Flow Cytometry Analysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Herpes virus infections, which are believed to be involved in the pathogenesis of multiple sclerosis (MS), may influence the distribution of Natural Killer receptors (NKR) in NK and CD8+ T cells. We evaluated in MS patients the NKR profile in these lymphocytes considering different clinical variables and treatment.


Multicolour flow cytometry analysis of NKR (NKG2D, LILRB1, NKG2A, NKG2C, KIR, NKp30 and NKp46) was performed in peripheral blood NK and CD8+ T cells from 41 healthy controls and 63 MS patients, adjusting clinical variables in multivariate regression analysis.


The proportions of CD8+ T cells displaying LILRB1, an inhibitory NKR expressed at late stages of T cell differentiation, were directly related with age (r 0.64, B 1.06; p<0.001) and MS duration (r 0.52, B 0.98; p<0.001), and inversely associated with interferon-β therapy (r -0.35, B -11.34; p<0.05); by contrast, no age-related NKR distribution was perceived in controls. Moreover, the proportions of LILRB1+ NK cells were associated with non-active MS in the previous two years (OR 0.93, CI95% 0.86-0.98, p<0.05). The number of CD56bright NK cells, a subset reported to expand after immunomodulatory therapy, negatively correlated with age and LILRB1+ lymphocytes, and was directly related with interferon-β treatment and female gender.


The immunophenotype observed in MS patients is consistent with a progressive accumulation of effector/memory T cells and experienced NK cells modulated by clinical course and interferon-β therapy. Further studies are required to validate the analysis of NK-associated molecules as potential biomarkers in MS clinical assessment.

Copyright information

© Martinez-Rodriguez and López-Botet; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Authors and Affiliations

  • J E Martinez-Rodriguez
    • 1
  • M López-Botet
    • 2
  1. 1.Neurology Dept.Hospital del Mar, IMIM, Parc de salut MarBarcelonaSpain
  2. 2.Immunology UnitUniversitat Pompeu FabraBarcelonaSpain

Personalised recommendations